Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15235296 | 0.89 | MME (0.35) | SMN1; SMN2MMECA1CA2CA14 | |
| SCHEMBL30515033 | 0.86 | MME (0.35) | SMN1; SMN2MMECA1CA2 | |
| SCHEMBL11652425 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2MMECA1CA2CA14 | |
| SCHEMBL25334504 | 0.83 | MME (0.30) | MME | |
| SCHEMBL3453810 | 0.81 | ALDH1A1 (0.40) | TSHRKMT2AALDH1A1 | |
| SCHEMBL3686978 | 0.80 | CA1 (0.43) | SMN1; SMN2MMECA1CA2CA14 | |
| SCHEMBL3687012 | 0.79 | MGAM (0.36) | SMN1; SMN2MMECA1CA2CA14 | |
| SCHEMBL10511072 | 0.79 | SLC1A1 (0.37) | MMEKMT2ANPC1 | |
| SCHEMBL10747616 | 0.78 | CA1 (0.38) | SMN1; SMN2MMECA1CA2CA14 | |
| SCHEMBL1059738 | 0.77 | MME (0.56) | SMN1; SMN2MMECA14CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630115-A1 | THERAPEUTIC COMPOUNDS | Sanofi (FR) | 2025-10-15 | — | — | EP | disclosed |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024121427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-2060557-B1 | Intermediate compounds useful to prepare dolasetron | INKE SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2060557-B1 | Intermediate compounds useful to prepare dolasetron | INKE SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| EP-2060557-A1 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060557-A1 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | DHPS, ALG8, DDOST | SMN1; SMN2 3531/4885MME 755/4885CA1 2468/4885 |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | SMN1; SMN2 1175/4885MME 1463/4885CA1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.